Status:
COMPLETED
Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
Lead Sponsor:
University of Cologne
Conditions:
Nephrocalcinosis
Eligibility:
All Genders
5-8 years
Phase:
PHASE3
Brief Summary
Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with \~ 7-10 % o...
Eligibility Criteria
Inclusion
- Preterm infants \< 32 weeks gestation age and \< 1500 g birth weight
Exclusion
- Cardial, renal or gastrointestinal malformations
- Chronic renal failure
- Therapy with vitamin B6
- High dose treatment with furosemide or dexamethasone
- Addison's disease
- Severe metabolic alkalosis
- Worse clinical condition of preterm infant, which makes oral feeding impossible
- Participation in other studies
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00249951
Start Date
November 1 2005
End Date
November 1 2008
Last Update
July 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. Bernd Hoppe
Cologne, Germany, D-50924